Decision: Favourable

Decisions Table

Study Title:

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

  • NREC Code:

    21-NREC-CT-001

  • Decision:

    Favourable

  • Meeting Date:

    02/06/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Prof. Ray McDermott

  • PI Institution:

    Tallaght University Hospital

  • Sponsor:

    Covance CAPS Limited by Merck Sharp & Dohme

Scroll to Top